Charles Brenner, PhD, director of the Obesity Initiative at the University of Iowa, discusses properties of nicotinamide riboside that have been uncovered since its initial discovery in 2004.
He discusses the positioning of JAK inhibitors in the treatment of inflammatory bowel disease, which he presented at the virtual AIBD regional meeting July 25.
David West, Jr, CEO and Founder of Proscia, discusses a new realm of digital pathology and how it can improve health care for doctors and patients.
